ASCO 2015: Dr. Maurie Markman gives his top picks in gynecologic research

Dr. Maurie Markman picks the upcoming ASCO presentations he anticipates to be the most interesting in gynecologic research.

• 5510 Antitumor activity and safety of pembrolizumab in patients (pts) with PD-L1 positive advanced ovarian cancer: Interim results from a phase Ib study.

• 5505 Retrospective analysis of candidate predictive tumor biomarkers (BMs) for efficacy in the GOG-0218 trial evaluating front-line carboplatin–paclitaxel (CP) ± bevacizumab (BEV) for epithelial ovarian cancer (EOC).

• 5506 An international, biomarker-directed, randomized, phase II trial of AZD1775 plus paclitaxel and carboplatin (P/C) for the treatment of women with platinum-sensitive, TP53-mutant ovarian cancer.

• 5508 Results of ARIEL2: A phase II trial to prospectively identify ovarian cancer patients likely to respond to rucaparib using tumor genetic analysis.

• 5503 Impact of trebananib plus weekly paclitaxel on overall survival (OS) in patients (pts) with recurrent ovarian cancer and ascites: Results from the phase III TRINOVA-1 study.

• 5502 Randomized phase II trial of carboplatin-paclitaxel (CP) compared to carboplatin-paclitaxel-bevacizumab (CP-B) in advanced (stage III-IV) or recurrent endometrial cancer: The MITO END-2 trial.

Dr. Maurie Markman is president, medicine and science, Cancer Treatment Centers of America.

Dr. Maurie Markman picks the upcoming ASCO presentations he anticipates to be the most interesting in gynecologic research.

• 5510 Antitumor activity and safety of pembrolizumab in patients (pts) with PD-L1 positive advanced ovarian cancer: Interim results from a phase Ib study.

• 5505 Retrospective analysis of candidate predictive tumor biomarkers (BMs) for efficacy in the GOG-0218 trial evaluating front-line carboplatin–paclitaxel (CP) ± bevacizumab (BEV) for epithelial ovarian cancer (EOC).

• 5506 An international, biomarker-directed, randomized, phase II trial of AZD1775 plus paclitaxel and carboplatin (P/C) for the treatment of women with platinum-sensitive, TP53-mutant ovarian cancer.

• 5508 Results of ARIEL2: A phase II trial to prospectively identify ovarian cancer patients likely to respond to rucaparib using tumor genetic analysis.

• 5503 Impact of trebananib plus weekly paclitaxel on overall survival (OS) in patients (pts) with recurrent ovarian cancer and ascites: Results from the phase III TRINOVA-1 study.

• 5502 Randomized phase II trial of carboplatin-paclitaxel (CP) compared to carboplatin-paclitaxel-bevacizumab (CP-B) in advanced (stage III-IV) or recurrent endometrial cancer: The MITO END-2 trial.

Dr. Maurie Markman is president, medicine and science, Cancer Treatment Centers of America.

Dr. Maurie Markman picks the upcoming ASCO presentations he anticipates to be the most interesting in gynecologic research.

• 5510 Antitumor activity and safety of pembrolizumab in patients (pts) with PD-L1 positive advanced ovarian cancer: Interim results from a phase Ib study.

• 5505 Retrospective analysis of candidate predictive tumor biomarkers (BMs) for efficacy in the GOG-0218 trial evaluating front-line carboplatin–paclitaxel (CP) ± bevacizumab (BEV) for epithelial ovarian cancer (EOC).

• 5506 An international, biomarker-directed, randomized, phase II trial of AZD1775 plus paclitaxel and carboplatin (P/C) for the treatment of women with platinum-sensitive, TP53-mutant ovarian cancer.

• 5508 Results of ARIEL2: A phase II trial to prospectively identify ovarian cancer patients likely to respond to rucaparib using tumor genetic analysis.

• 5503 Impact of trebananib plus weekly paclitaxel on overall survival (OS) in patients (pts) with recurrent ovarian cancer and ascites: Results from the phase III TRINOVA-1 study.

• 5502 Randomized phase II trial of carboplatin-paclitaxel (CP) compared to carboplatin-paclitaxel-bevacizumab (CP-B) in advanced (stage III-IV) or recurrent endometrial cancer: The MITO END-2 trial.

Dr. Maurie Markman is president, medicine and science, Cancer Treatment Centers of America.